...
VRTXLARGE

Vertex Pharmaceuticals Incorporated

HealthcareBiotechnology
$496.83
$0.17(+3.48%)
52W$362.50
$519.68
FinancialsValuationvs AGIO
Updated Mar 1, 12:00 AM
RSI55
RS Rating69/99
Beta0.44
Volatility34%
F-Score5/9
Mkt Cap$126.2B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Vertex Pharmaceuticals Incorporated is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 69), indicating performance broadly in line with the market. Earnings growth of 5% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
69
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.44
vs S&P 500
LOW VOL
52W Position
85%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$466.12
50 SMA > 100 SMA$446.99
100 SMA > 150 SMA$431.11
150 SMA > 200 SMA$436.41

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$474.84+4.63%ABOVE
50 SMA$466.12+6.59%ABOVE
100 SMA$446.99+11.15%ABOVE
150 SMA$431.11+15.24%ABOVE
200 SMA$436.41+13.84%ABOVE

Price Performance

1D+3.5%
1W+3.3%
1M+4.0%
3M+14.6%
6M+26.7%
YTD+9.9%
1Y+3.6%
3Y+19.6%
52-Week Trading Range85% from low
$496.83
52W Low$362.50
52W High$519.68

Technical Indicators

RSI (14)NEUTRAL
54.6
305070
VCP ScoreHOT
7/10
Base depth: 15.1%

Risk Profile

Beta
0.44
52W Vol
34%
ATR
$13.96
Max DD (1Y)
-29%

Volume Analysis

Today
496
50D Avg
1.20M
Vol Ratio
0.00x
Liquidity
VERY LIQUID

Earnings Momentum

Q4'24-6%
$3.50
Q1'25-41%
$2.49
Q2'25+129%
$3.99
Q3'25+5%
$4.20
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+27.80%
5 Years:+14.10%
3 Years:+10.35%
TTM:+10.36%

Compounded Profit Growth

10 Years:—
5 Years:+8.29%
3 Years:+6.12%
TTM:+8.13%

Stock Price CAGR

10 Years:+19.24%
5 Years:+18.75%
3 Years:+19.62%
1 Year:+3.55%

Return on Equity

10Y Avg:22.5%
5Y Avg:19.0%
3Y Avg:14.1%
Last Year:21.2%

Key Metrics

Market Cap$126.2B
Gross Margin86.2%
Net Margin32.9%
Piotroski F-Score5/9

More VRTX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

VRTX vs AGIOAGIOASNDBBIOBMRN

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 69 meansVRTX outperformed 69% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.44 means 56% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 7/10 with HOT status.

Frequently Asked Questions

Is VRTX in an uptrend right now?

VRTX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is VRTX overbought or oversold?

VRTX's RSI (14) is 55. The stock is in neutral territory, neither overbought nor oversold.

Is VRTX outperforming the market?

VRTX has a Relative Strength (RS) Rating of 69 out of 99. VRTX is performing about average compared to the market.

Where is VRTX in its 52-week range?

VRTX is trading at $496.83, which is 96% of its 52-week high ($519.68) and 85% above its 52-week low ($362.50).

How volatile is VRTX?

VRTX has a Beta of 0.44 and 52-week volatility of 34%. It's less volatile than the S&P 500 - generally more stable.